Research Article
lncRNA PCAT14 Is a Diagnostic Marker for Prostate Cancer and Is Associated with Immune Cell Infiltration
Table 1
Correlation between PCAT14 and clinical indicators of patients.
| | Low expression of PCAT14 | High expression of PCAT14 | |
| | 249 | 250 | | T stage, (%) | | | 0.005 | T2 | 76 (15.4%) | 113 (23%) | | T3 | 160 (32.5%) | 132 (26.8%) | | T4 | 7 (1.4%) | 4 (0.8%) | | N stage, (%) | | | 0.009 | N0 | 169 (39.7%) | 178 (41.8%) | | N1 | 52 (12.2%) | 27 (6.3%) | | M stage, (%) | | | 0.249 | M0 | 230 (50.2%) | 225 (49.1%) | | M1 | 3 (0.7%) | 0 (0%) | | Primary therapy outcome, (%) | | | 0.022 | PD | 16 (3.7%) | 12 (2.7%) | | SD | 18 (4.1%) | 11 (2.5%) | | PR | 27 (6.2%) | 13 (3%) | | CR | 156 (35.6%) | 185 (42.2%) | | Race, (%) | | | 0.195 | Asian | 9 (1.9%) | 3 (0.6%) | | Black or African American | 30 (6.2%) | 27 (5.6%) | | White | 204 (42.1%) | 211 (43.6%) | | Age, (%) | | | 0.342 | ≤60 | 106 (21.2%) | 118 (23.6%) | | >60 | 143 (28.7%) | 132 (26.5%) | | Residual tumor, n (%) | | | <0.001 | R0 | 133 (28.4%) | 182 (38.9%) | | R1 | 100 (21.4%) | 48 (10.3%) | | R2 | 1 (0.2%) | 4 (0.9%) | | PSA (ng/ml), (%) | | | 0.347 | <4 | 199 (45%) | 216 (48.9%) | | ≥4 | 16 (3.6%) | 11 (2.5%) | | Gleason score, (%) | | | < 0.001 | 6 | 16 (3.2%) | 30 (6%) | | 7 | 103 (20.6%) | 144 (28.9%) | | 8 | 34 (6.8%) | 30 (6%) | | 9 | 92 (18.4%) | 46 (9.2%) | | 10 | 4 (0.8%) | 0 (0%) | | OS event, (%) | | | 0.339 | Alive | 246 (49.3%) | 243 (48.7%) | | Dead | 3 (0.6%) | 7 (1.4%) | | Age, | | | 0.020 | PSA (ng/ml), | | | 0.179 |
|
|
PD: progressive disease; SD: stable disease; PR: partial response; CR: complete response; PSA: prostate-specific antigen; OS: overall survival.
|